FATE · Fate Therapeutics Inc
$2.57
+0.05 (+1.98%)
At close · Aug 14
Market Cap
$307.94M
Shares
119.82M
Fate Therapeutics Inc Earnings Call Transcripts
Every quarterly earnings call for Fate Therapeutics Inc (FATE) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲94%
$5.46M
−$28.07M
'20 Q2
20-08-05
▲211.2%
$7.56M
−$58.68M
'20 Q3
20-11-05
▲467.3%
$15.90M
−$53.11M
'20 Q4
21-02-24
▲343%
$11.14M
−$45.09M
'21 Q1
21-05-05
▲145.4%
$13.41M
−$55.13M
'21 Q2
21-08-04
▲88.2%
$14.22M
−$43.31M
'21 Q3
21-11-04
▲7.4%
$17.07M
−$68.62M
'21 Q4
22-02-28
▲65.3%
$18.41M
−$65.69M
'22 Q1
22-05-04
▲38.3%
$18.55M
−$76.11M
'22 Q2
22-08-03
▲5.3%
$14.98M
−$83.56M
'22 Q3
22-11-03
▲159.9%
$44.36M
−$56.36M
'22 Q4
23-02-28
▲220.3%
$58.98M
−$18.88M
'23 Q1
23-05-03
▼95%
$933,000
−$52.76M
'23 Q2
23-08-08
▼87%
$1.94M
−$45.17M
'23 Q3
23-11-08
▼96.2%
$1.68M
−$44.12M
'23 Q4
24-02-26
LATEST
▼96.7%
$1.93M
−$48.00M
'24 Q1
24-05-09
Earnings call
FY24 · Q1
2024-05-09
Fate Therapeutics Inc Q1 FY2024 Earnings Call
Confident tone
FT819 clinical data in autoimmunity
FT522 CAR NK cell program
Pipeline focus and strategic prioritization
Revenue
$1.93M
▼ 96.7% YoY Diluted EPS
$-0.47
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-26
Fate Therapeutics Inc Q4 FY2023 Earnings Call
Confident tone
FT819 CD19 CAR T-cell program
Autoimmunity expansion
FT522 NK cell program with ADR technology
Revenue
$1.68M*
▼ 96.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Fate Therapeutics Inc Q3 FY2023 Earnings Call
Revenue
$1.94M
▼ 87% YoY Diluted EPS
$-0.46
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Fate Therapeutics Inc Q2 FY2023 Earnings Call
Revenue
$933,000
▼ 95% YoY Diluted EPS
$-0.54
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Fate Therapeutics Inc Q1 FY2023 Earnings Call
Revenue
$58.98M
▲ 220.3% YoY Diluted EPS
$-0.19
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Fate Therapeutics Inc Q4 FY2022 Earnings Call
Revenue
$44.36M*
▲ 159.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Fate Therapeutics Inc Q3 FY2022 Earnings Call
Revenue
$14.98M
▲ 5.3% YoY Diluted EPS
$-0.86
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Fate Therapeutics Inc Q2 FY2022 Earnings Call
Revenue
$18.55M
▲ 38.3% YoY Diluted EPS
$-0.79
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Fate Therapeutics Inc Q1 FY2022 Earnings Call
Revenue
$18.41M
▲ 65.3% YoY Diluted EPS
$-0.68
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Fate Therapeutics Inc Q4 FY2021 Earnings Call
Revenue
$17.07M*
▲ 7.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Fate Therapeutics Inc Q3 FY2021 Earnings Call
Revenue
$14.22M
▲ 88.2% YoY Diluted EPS
$-0.45
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Fate Therapeutics Inc Q2 FY2021 Earnings Call
Revenue
$13.41M
▲ 145.4% YoY Diluted EPS
$-0.58
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Fate Therapeutics Inc Q1 FY2021 Earnings Call
Revenue
$11.14M
▲ 343% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-24
Fate Therapeutics Inc Q4 FY2020 Earnings Call
Revenue
$15.90M*
▲ 467.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Fate Therapeutics Inc Q3 FY2020 Earnings Call
Revenue
$7.56M
▲ 211.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Fate Therapeutics Inc Q2 FY2020 Earnings Call
Revenue
$5.46M
▲ 94% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Fate Therapeutics Inc Q1 FY2020 Earnings Call
Revenue
$2.52M
▼ 4.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-02
Fate Therapeutics Inc Q4 FY2019 Earnings Call
Revenue
$2.80M
▲ 68.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–18 of 18 earnings calls
Key facts
CIK
1434316
CUSIP
31189P102
13F (30d)
145 filings
144 filers
Visit website
Investor relations